Literature DB >> 23904276

Insulin secretion and sensitivity in the prediction of type 1 diabetes in children with advanced β-cell autoimmunity.

Heli T Siljander1, Robert Hermann, Anne Hekkala, Jyrki Lähde, Laura Tanner, Päivi Keskinen, Jorma Ilonen, Olli Simell, Riitta Veijola, Mikael Knip.   

Abstract

OBJECTIVE: Reduced early insulin response has been shown to predict type 1 diabetes (T1D) in first-degree relatives of diabetic patients, while its role, as well as that of insulin resistance, has remained poorly defined in young children representing the general population. The predictive values of these markers and their relation to other risk factors of T1D were assessed in children with advanced β-cell autoimmunity, i.e. persistent positivity for two or more autoantibodies. DESIGN AND METHODS: Intravenous glucose tolerance tests (IVGTTs) were carried out in 218 children with HLA-DQB1-conferred disease susceptibility and advanced β-cell autoimmunity. Baseline, metabolic and growth data were compared between children progressing to diabetes and those remaining unaffected. Hazard ratios for the disease predictors and the progression rate of T1D were assessed.
RESULTS: Children developing T1D were younger at seroconversion, progressed more rapidly to advanced β-cell autoimmunity and had lower first-phase insulin response (FPIR) and homeostasis model assessment index for insulin resistance (HOMA-IR) than those remaining non-diabetic. The levels of HOMA-IR/FPIR, islet cell antibodies, insulin autoantibodies (IAA) and islet antigen 2 antibodies (IA-2A) were higher in progressors. BMI SDS, FPIR, age at IVGTT and levels of IAA and IA-2A were predictive markers for T1D.
CONCLUSIONS: Young age, higher BMI SDS, reduced FPIR and higher levels of IAA and IA-2A predicted T1D in young children with HLA-DQB1-conferred disease susceptibility and advanced β-cell autoimmunity. Disease risk estimates were successfully stratified by the assessment of metabolic status and BMI. The role of insulin resistance as an accelerator of the disease process was minor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904276     DOI: 10.1530/EJE-13-0206

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  13 in total

Review 1.  Environmental factors in the etiology of type 1 diabetes, celiac disease, and narcolepsy.

Authors:  Åke Lernmark
Journal:  Pediatr Diabetes       Date:  2016-07       Impact factor: 4.866

2.  Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes.

Authors:  Arianne Aslamy; Eunjin Oh; Miwon Ahn; Abu Saleh Md Moin; Mariann Chang; Molly Duncan; Jeannette Hacker-Stratton; Mohamed El-Shahawy; Fouad Kandeel; Linda A DiMeglio; Debbie C Thurmond
Journal:  J Clin Endocrinol Metab       Date:  2018-05-01       Impact factor: 5.958

3.  Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.

Authors:  Annelien Van Dalem; Simke Demeester; Eric V Balti; Katelijn Decochez; Ilse Weets; Evy Vandemeulebroucke; Ursule Van de Velde; An Walgraeve; Nicole Seret; Christophe De Block; Johannes Ruige; Pieter Gillard; Bart Keymeulen; Daniel G Pipeleers; Frans K Gorus
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

4.  OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis.

Authors:  Olli Helminen; Susanna Aspholm; Tytti Pokka; Jorma Ilonen; Olli Simell; Riitta Veijola; Mikael Knip
Journal:  Diabetologia       Date:  2015-05-19       Impact factor: 10.122

5.  Residual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Hang Xiang; Chao Yang; Tianyuan Xiang; Zheng Wang; Xin Ge; Fan Li; Yuehan Su; Haixu Chen; Xianyong Huang; Qiang Zeng
Journal:  Stem Cells Transl Med       Date:  2016-03-29       Impact factor: 6.940

6.  Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.

Authors:  Emily K Sims; Brian N Bundy; Kenneth Stier; Elisavet Serti; Noha Lim; S Alice Long; Susan M Geyer; Antoinette Moran; Carla J Greenbaum; Carmella Evans-Molina; Kevan C Herold
Journal:  Sci Transl Med       Date:  2021-03-03       Impact factor: 17.956

7.  Reduced β-cell function in early preclinical type 1 diabetes.

Authors:  Maarit K Koskinen; Olli Helminen; Jaakko Matomäki; Susanna Aspholm; Juha Mykkänen; Marjaana Mäkinen; Ville Simell; Mari Vähä-Mäkilä; Tuula Simell; Jorma Ilonen; Mikael Knip; Riitta Veijola; Jorma Toppari; Olli Simell
Journal:  Eur J Endocrinol       Date:  2015-11-30       Impact factor: 6.664

8.  Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Authors:  Annelien Van Dalem; Simke Demeester; Eric V Balti; Bart Keymeulen; Pieter Gillard; Bruno Lapauw; Christophe De Block; Pascale Abrams; Eric Weber; Ilse Vermeulen; Pieter De Pauw; Daniël Pipeleers; Ilse Weets; Frans K Gorus
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

9.  Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.

Authors:  Michael G Voss; David D Cuthbertson; Mario M Cleves; Ping Xu; Carmella Evans-Molina; Jerry P Palmer; Maria J Redondo; Andrea K Steck; Markus Lundgren; Helena Larsson; Wayne V Moore; Mark A Atkinson; Jay M Sosenko; Heba M Ismail
Journal:  Diabetes Care       Date:  2021-08-06       Impact factor: 17.152

Review 10.  Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes.

Authors:  Emily K Sims; Linda A DiMeglio
Journal:  Mol Metab       Date:  2019-09       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.